- Home
- HLF vs GHRS Comparison
HLF vs GHRS Comparison
Compare HLF & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLF
- GHRS
- Stock Information
- Founded
- HLF 1980
- GHRS 2018
- Country
- HLF United States
- GHRS Ireland
- Employees
- HLF N/A
- GHRS N/A
- Industry
- HLF Other Pharmaceuticals
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- HLF Health Care
- GHRS Health Care
- Exchange
- HLF Nasdaq
- GHRS Nasdaq
- Market Cap
- HLF 824.8M
- GHRS 774.1M
- IPO Year
- HLF N/A
- GHRS 2021
- Fundamental
- Price
- HLF $8.05
- GHRS $13.50
- Analyst Decision
- HLF Strong Buy
- GHRS Strong Buy
- Analyst Count
- HLF 4
- GHRS 9
- Target Price
- HLF $11.50
- GHRS $29.33
- AVG Volume (30 Days)
- HLF 1.3M
- GHRS 278.7K
- Earning Date
- HLF 11-05-2025
- GHRS 11-07-2025
- Dividend Yield
- HLF N/A
- GHRS N/A
- EPS Growth
- HLF 285.96
- GHRS N/A
- EPS
- HLF 3.17
- GHRS N/A
- Revenue
- HLF $4,928,500,000.00
- GHRS N/A
- Revenue This Year
- HLF $1.02
- GHRS N/A
- Revenue Next Year
- HLF $4.52
- GHRS N/A
- P/E Ratio
- HLF $2.52
- GHRS N/A
- Revenue Growth
- HLF N/A
- GHRS N/A
- 52 Week Low
- HLF $5.04
- GHRS $6.72
- 52 Week High
- HLF $10.83
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- HLF 38.10
- GHRS 49.82
- Support Level
- HLF $7.56
- GHRS $12.50
- Resistance Level
- HLF $8.32
- GHRS $14.77
- Average True Range (ATR)
- HLF 0.30
- GHRS 0.99
- MACD
- HLF -0.04
- GHRS -0.00
- Stochastic Oscillator
- HLF 34.96
- GHRS 44.04
About HLF Herbalife Ltd.
Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.